Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in adva...
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
About this item
Full title
Author / Creator
Yuan, Shumin , Peng, Ling , Liu, Yuqing , Till, Brian G. , Yan, Xiang , Zhang, Jie , Zhu, Liping , Wang, Huijuan , Zhang, Shaokai , Li, Hongle , Gao, Quanli and Wang, Zibing
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Background
Anti-angiogenic drugs increase anti-tumor efficacy of immune checkpoint inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs remains unclear.
Methods
We retrospectively analyzed efficacy and safety data from patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) that received PD-1 bloc...
Alternative Titles
Full title
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991614
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991614
Other Identifiers
ISSN
0340-7004,1432-0851
E-ISSN
1432-0851
DOI
10.1007/s00262-022-03259-5
